Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Adding bimagrumab 30 mg/kg to semaglutide 2.4 mg conferred weight loss of more than 20% at 72 weeks in patients ... focused on the results of the three maximum-dose groups: bimagrumab 30 mg/kg, ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the lower dose and 2.4% in the placebo group.

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average.

Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a lower dose of medication.